Enanta Pharmaceuticals (ENTA) vs Relmada Therapeutics (RLMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Relmada Therapeutics (RLMD) has outperformed Enanta Pharmaceuticals (ENTA) over the past year, gaining 63.3% versus a gain of 11.6%. Over five years, ENTA leads with a -82.7% price change compared with -86.2% for RLMD. Enanta Pharmaceuticals is the larger company by market cap ($360.3 million vs $346.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENTA | RLMD |
|---|---|---|
| Share price | $12.37 | $3.25 |
| Market cap | $360.28M | $346.68M |
| 1-day change | +1.64% | -0.91% |
| YTD return | -21.56% | -32.71% |
| 1-year return | +11.64% | +63.32% |
| 5-year return | -82.69% | -86.25% |
| EPS (TTM) | $-2.47 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.15 | $8.00 |
| 52-week low | $10.20 | $1.80 |
| Distance from 52-week high | -27.87% | -59.38% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +76.48% | +230.77% |
| Average volume | 227.13K | 1.34M |
| Shares outstanding | 29.13M | 106.67M |
| Employees | 120 | 17 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLMD has outperformed ENTA by 51.7 percentage points over the past year.
About Enanta Pharmaceuticals
ENTA stock →Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.
Healthcare · Biotechnology · 120 employees
About Relmada Therapeutics
RLMD stock →Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
Healthcare · Biotechnology · 17 employees
ENTA vs RLMD FAQ
Which is bigger, Enanta Pharmaceuticals or Relmada Therapeutics?
Enanta Pharmaceuticals (ENTA) is larger, with a market capitalization of $360.28M compared with $346.68M for Relmada Therapeutics (RLMD).
Which stock has performed better over the past year, ENTA or RLMD?
RLMD returned +63.32% over the past 12 months, compared with +11.64% for ENTA (price return, excluding dividends). Past performance does not predict future results.
Are Enanta Pharmaceuticals and Relmada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.